Close
[adinserter block="1"]

Medication Adherence in Elderly Patients with Chronic Conditions

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...
- Advertisement -

The aging population is accompanied by an increased prevalence of chronic conditions, necessitating the management of complex medical regimens.

According to the National Institutes of Health (NIH), the average geriatric patient with chronic illness is prescribed at least five medications. While these medications are essential for controlling and mitigating the impact of chronic conditions, their adherence in the elderly poses a significant challenge.

Several factors contribute to the complexity of medication adherence in geriatric patients with chronic illnesses. These include intricate medication schedules, limited understanding of the disease as well as physical, economic, and logistic obstacles.

Another distinctive aspect of medication compliance among the elderly is the tendency to discontinue them autonomously once they perceive an amelioration in symptoms.

This autonomous decision-making process may arise from a lack of awareness regarding the long-term nature of chronic illnesses. It may even be a result of a misconception that the prescribed medications are no longer necessary. In this context, exploring the intricacies of medication adherence in elderly patients with chronic conditions becomes paramount.

In this article, we will discuss the prevalent issues and underscore the significance of holistic approaches to medication management.

Factors Affecting Medication Adherence

Cognitive impairments and memory problems in the elderly contribute to the difficulty in maintaining adherence. Additionally, financial barriers present challenges, especially for those on fixed incomes, creating obstacles in accessing and consistently acquiring prescribed medications.

A lack of understanding regarding the importance of medications and their long-term effects further complicates the compliance process.

Mental health conditions, particularly depression, play a crucial role in medication adherence. Depression may lead to a disinterest in treatment or a lack of motivation to adhere to prescribed regimens. The phenomenon of polypharmacy, where individuals are prescribed multiple medications concurrently, introduces another layer of complexity.

Social and cultural factors influence compliance, with varying beliefs and practices impacting how medications are perceived and used.

Frontiers report a significant global increase in the incidence of type 2 diabetes. It emphasizes the critical importance of adherence to medication regimens. The International Diabetes Federation (IDF) warns of a potential surge in diabetes cases. It projects that the cases could reach 700 million globally by 2045 if effective measures are not implemented.

The associated complications from the disease, including blindness and kidney disease, are preventable. Yet the asymptomatic nature of diabetes complicates long-term treatment adherence.

Strategies to Improve Medication Adherence in Elderly Patients

Patient education plays a pivotal role in empowering individuals with the knowledge and understanding necessary to adhere to prescribed regimens.

As reported by Fox 8, the significance of this educational approach is underscored by the example of UpStream, a company based in Greensboro. UpStream has a mission to enhance the effectiveness of primary care physicians in managing elderly patients.

Acknowledging the considerable challenges physicians face, especially when addressing chronic in the elderly population, UpStream strives to ease this burden. The company achieves this by facilitating comprehensive care through collaborations with healthcare providers, such as Cone Health.

The initiative recognizes the need for a coordinated approach to meet the complex healthcare requirements of the aging demographic.

Simplified medication regimens address the issue of complexity, making it easier for elderly patients to follow prescribed courses. Furthermore, the use of medication reminders and organizers, facilitated by technological advancements, further aids in adherence.

Medication reviews by pharmacists and healthcare providers ensure that drug regimens are optimized, minimizing adverse effects and interactions. Financial barriers, a significant impediment to compliance, can be mitigated through innovative solutions and partnerships.

Furthermore, the incorporation of caregivers into the medication management process offers elderly patients invaluable advantages. The caregivers provide additional support, supervision, and assistance in adhering to their prescribed medications.

A home care agency in Greensboro, as well as in other locations, boasts trained professionals who specialize in medication management. These caregivers play a crucial role in ensuring that seniors adhere to their medication regimens consistently.

Always Best Care Senior Services notes that their expertise promotes safety and addresses any concerns seniors may have about medications. This personalized approach contributes to better health outcomes, improved overall well-being, and a heightened sense of security for elderly individuals.

Role of Healthcare Providers in Promoting Medication Adherence

The role of healthcare providers in promoting medication compliance among the elderly population is pivotal for optimizing health outcomes. Establishing strong patient-provider relationships serves as a foundation for successful adherence. By building trust, healthcare providers can gain insights into patients’ unique circumstances, facilitating a more personalized approach to care.

Tailoring treatment plans to individual patient needs is essential. Recognizing the diverse factors influencing adherence, healthcare providers can collaborate with patients to develop regimens that align with their health goals.

Clear and concise medication instructions play a crucial role in ensuring patients understand the importance of the correct administration.

Regular monitoring of patient progress is a proactive measure to identify any challenges or concerns related to adherence promptly.

Healthcare providers can address issues such as side effects, financial constraints, or lifestyle adjustments, adapting treatment plans as needed. Collaboration with pharmacists and other healthcare providers enhances the continuum of care, allowing for comprehensive medication management.

In sum, the role of healthcare providers extends beyond prescribing medications. It encompasses creating a supportive environment that empowers patients to adhere to their treatment plans

Impact of Medication Adherence on Patient Outcomes

Rigorous compliance to medication regimens correlates directly with improved symptom control, leading to a heightened quality of life for patients. When individuals consistently follow their prescribed treatment plans, the risk of hospitalization and emergency department visits significantly decreases.

This contributes to a more stable and predictable health status and minimizes the strain on healthcare resources.

Moreover, adherence to medication plays a pivotal role in lowering overall healthcare costs. By preventing complications and disease exacerbations through consistent medication use, patients are less likely to require intensive medical interventions.

In summary, increased survival rates are observed among patients who adhere to their prescribed medications. The ability of medications to manage chronic conditions effectively directly influences the long-term prognosis and survival outcomes. Ultimately, medication adherence emerges as a cornerstone in achieving positive health outcomes, enhancing patient well-being, and a sustainable healthcare landscape.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...

Danaher Prepares to Introduce Advanced AI-Powered Laboratory

In a significant step for pharmaceutical research, Danaher has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »